Clinical trials: Brain Age
Homocystinuria
A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)
The goal of this long-term extension (LTE) study is to evaluate the safety and efficacy of pegtibatinase in patients with classical homocystinuria (HCU).
- Trial name
- ENSEMBLE (NCT06431893)
- Testing
- Pegtibatinase
- Where
- 52 sites in United States, Australia and 12 more
- Volunteers
- 100 people
- Sponsor
- Travere Therapeutics, Inc.
Epilepsy
Pediatric Epilepsy Study
This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as monotherapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.
- Trial name
- NCT00050947
- Testing
- oxcarbazepine
- Where
- 30 sites in United States, Brazil and 2 more
- Volunteers
- 94 people
- Sponsor
- Novartis Pharmaceuticals
Lower Limb Spasticity Due to Cerebral Palsy
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy
The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the leg(s) are effective in treating children/adolescents (age 2-17 years) with increased muscle tension/uncontrollable muscle…
- Trial name
- NCT01893411
- Testing
- IncobotulinumtoxinA (16 Units per kg body weight), IncobotulinumtoxinA (12 Units per kg body weight), IncobotulinumtoxinA (4 Units per kg body weight)
- Where
- 53 sites in Austria, Czechia and 12 more
- Volunteers
- 311 people
- Sponsor
- Merz Pharmaceuticals GmbH
Dementia, Alzheimer's Disease
Memory Disorders Registry
The study is designed to collect data regarding the clinical course and outcome of patients suffering from memory disorders. Visits are charged to the individual's insurance inclusive of Medicare.
- Conditions
- Dementia, Alzheimer's Disease, Parkinson Disease, Huntington Disease
- Trial name
- NCT00654563
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Cedars-Sinai Medical Center
Neurodegenerative Diseases, Aging
Simulation-informed Modelling and Personalized Evaluation (SIMPLE) in Ageing Populations
Multimodal magnetic resonance imaging (MRI), detecting brain structural and functional changes, has emerged as a powerful and promising technique to study individual's brain, as T1-weighted scans can detect morphometric features…
- Conditions
- Neurodegenerative Diseases, Aging, Brain, Cognitive Dysfunction
- Trial name
- NCT06572332
- Where
- Hong Kong
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Delirium, Aging
A Trial to Reduce Delirium in Aged Post Acute Patients
The purpose of this study is to develop a comprehensive Delirium Abatement Program of care of delirious patients in the post acute care setting and to evaluate its impact on persistence and severity of delirium and on functional…
- Trial name
- NCT00182936
- Testing
- Delirium Abatement Program
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Institute on Aging (NIA)
Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis)
Biofluid Research on Age-Related or Inherited Neurodegeneration
The aim of this study is to contribute to and continue to sustain a repository of blood samples, nucleic acid (DNA and/or RNA) samples, family history information, and other demographic information from individuals with…
- Conditions
- Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis), Primary Progressive Aphasia (PPA), Familial Frontotemporal Lobar Degeneration (fFTLD)
- Trial name
- BRAIN (NCT07798700)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Cerebrovascular Disorders, Gait Disorders, Neurologic
Application of Device-based Training to Improve Postural Control in Older Adults With CCI
The goal of this clinical trial is to improve comprehensive rehabilitation programs for elderly patients with chronic cerebral ischemia by incorporating training methods with biofeedback for postural control training.
- Conditions
- Cerebrovascular Disorders, Gait Disorders, Neurologic, Accidental Fall, Aged
- Trial name
- NCT07358338
- Testing
- "Huber" (LPG-Systems, France), "C-mill" (Physiomed Elektromedizin AG, Germany), Physical therapy
- Where
- Russia
- Volunteers
- 120 people
- Sponsor
- Litvina Lyubov Dmitrievna
Healthy
Diet and the Aging Brain
We investigate whether a change in diet could provide positive effects on general brain functions in healthy elderly people.
- Trial name
- NCT00463255
- Testing
- diet
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Hospital Muenster
Juvenile Myoclonic Epilepsy
A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy
This study is being conducted to evaluate the safety and efficacy of JZP926 capsule in participants with Juvenile Myoclonic Epilepsy (JME).
- Trial name
- NCT07723963
- Testing
- JZP926 capsule
- Where
- 20 sites in United States
- Volunteers
- 260 people
- Sponsor
- Jazz Pharmaceuticals
Partial-Onset or Primary Generalized Tonic-Clonic Seizures
Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures
This is an open-label, multicenter study with an Extension Phase to evaluate the safety and tolerability of perampanel oral suspension when administered as an adjunctive therapy in children (ages 4 to less than [<] 12 years) with…
- Trial name
- NCT02849626
- Testing
- Perampanel
- Where
- 91 sites in United States, Belgium and 10 more
- Volunteers
- 180 people
- Sponsor
- Eisai Inc.
Traumatic Brain Injury, Cerebral Edema
Safety and Efficacy of ABX-101 in Participants Aged 18 to 50 Years of Age With Moderate to Severe Traumatic Brain Injury
The purpose of this study is to investigate the clinical improvement measured by the Glasgow Outcome Scale Extended (GOS-E) with ABX-101 compared with Placebo intramuscular injection in participants with moderate to severe TBI.
- Trial name
- NCT06096415
- Testing
- ABX-101 1mg, ABX-101 2mg
- Volunteers
- 45 people
- Sponsor
- Abalonex, LLC
Friedreich Ataxia
A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
The primary objective of the study is to assess the pharmacokinetics (PK) and safety of vatiquinone administered in participants with Friedreich ataxia (FA) younger than 7 years.
- Trial name
- NCT05485987
- Testing
- Vatiquinone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- PTC Therapeutics
Aging, Dementia Alzheimers
Localized Analysis of Normalized Distance From Scalp to Cortex and Personalized Evaluation (LANDSCAPE)
Scalp to cortex distance (SCD), as a key technological parameter of brain stimulation, has been highlighted in the guidelines of non-invasive brain stimulation.
- Conditions
- Aging, Dementia Alzheimers, Parkinson Disease, Dementia Frontotemporal
- Trial name
- NCT05967390
- Testing
- Transcranial Magnetic Stimulation
- Where
- Hong Kong
- Volunteers
- 488 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Seizure Disorders
A Taste and Acceptance Study of FruitiVits in Children Aged 4-8 Years Following a Ketogenic Diet.
Subjects will be asked to substitute their usual vitamin and mineral supplement/s with FruitiVits for seven consecutive days.
- Trial name
- FruitiVits (NCT02229318)
- Testing
- FruitiVits
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Vitaflo International, Ltd
Fabry Disease, Aged 65 Years or Older
Study of the Quality of Life of Patients With Fabry Disease Aged 65 and Over With and Without Specific Treatment
Fabry disease is a rare genetic disorder affecting 1 in 10,000 individuals, leading to complications such as chronic pain, heart and kidney failure, and strokes, ultimately impacting life expectancy.
- Conditions
- Fabry Disease, Aged 65 Years or Older, Alpha Galactosidase A Deficiency, Galactosidase A Gene Mutation
- Trial name
- FABRY65 (NCT07277361)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Wladimir MAUHIN, Dr
Alzheimer's Disease, Mild Cognitive Impairment
Alzheimer's Disease Core Center
The main objective of this research project is to provide a comprehensive clinical database of patients with Alzheimer's disease (AD) and other forms of dementia, individuals with mild cognitive impairment (MCI), and age-matched…
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Age-Related Memory Disorders
- Trial name
- ADCC (NCT01421420)
- Where
- United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Cognitive Impairment, Cardiovascular Risk Factor
Cognitive Impairment and Cardiovascular Risk in Older
The objective of this project is to study cognitive yields in people of the town of Salamanca over 65, with particular emphasis on the acquisition of the initial symptoms of cognitive impairment in order to detect mild cognitive…
- Trial name
- DECRIVAM (NCT01327196)
- Where
- Spain
- Volunteers
- 327 people
- Sponsor
- Fundacion para la Investigacion y Formacion en Ciencias de la Salud
Age-related Cognitive Decline, Mild Cognitive Impairment
The Active Mind Trial: An Adaptive Randomized Trial to Improve Function and Delay Dementia
Older adults at risk for dementia show a variety of cognitive deficits, which can be ameliorated by different cognitive training (CT) exercises. The best combination of CT exercises is unknown.
- Conditions
- Age-related Cognitive Decline, Mild Cognitive Impairment, Dementia
- Trial name
- NCT04171323
- Testing
- Cognitive Training, Computerized Cognitive Stimulation
- Where
- 6 sites in United States
- Volunteers
- 1,305 people
- Sponsor
- University of Alabama at Birmingham
Glycogen Storage Disease Type II
A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)
Primary Objective: To describe the effect of routine practice with alglucosidase alfa in patients with IOPD ≤6 months of age, on invasive ventilation-free survival after 52 weeks of treatment.
- Trial name
- NCT04848779
- Testing
- Alglucosidase alfa GZ419829
- Where
- 15 sites in United States, Belgium and 7 more
- Volunteers
- 16 people
- Sponsor
- Sanofi